Fighting Cancer

Every Step of the Way

Vigilant Biosciences is transforming the early detection and intervention of cancer.

Learn More
vb-homepage-image3

Dedicated to Early Intervention. And Life.


Vigilant Biosciences is a leading innovator and developer of solutions that aid in the early detection and intervention of cancer. Its OncAlert™ Oral Cancer Risk Assessment System uses patented technology that is highly-accurate and specific.

Learn More
Did You Know?

When diagnosed early, oral cancer patients have an 80 to 90% survival rate.

Unfortunately, over 40% of those diagnosed with oral cancer will die within five years due to these cases being discovered as a late stage malignancy.

Learn More

At A Glance

Transforming Early Detection

Vigilant Biosciences’ products are based on patented technology that detects specific protein markers known to clinically show elevated risk for early stage cancers, even prior to observation of visual or physical symptoms... more


Easy-to-Use and Non-Invasive

OncAlert™ products utilize a simple oral rinse procedure that is easy to administer and non-invasive for the patient... more


Accurate and Objective Results at the Point-of-Care or Lab

Both the rapid point-of-care test and the lab assay that comprise the OncAlert™ system provide a timely, accurate, and specific risk assessment for oral cancer... more

MORE ABOUT VIGILANT'S ONCALERT™ TECHNOLOGY

News + Press

  • vb-400x210

    Vigilant Biosciences™ to Exhibit and Present at International Dental Show 2015

    Company to Debut its OncAlert Oral Cancer Risk Assessment System for Assessment and Intervention of Early Stage Oral Cancer MIAMI — Vigilant Biosciences, Inc. (“Vigilant”), a leading innovator and developer of solutions that aid in the early detection and intervention of…more

  • dentistryIQ

    Dentistry iQ Newscast

    Erin Robinson interviews Matthew Kim, Founder and Chief Executive Officer of Vigilant Biosciences, Inc., at the Chicago Midwinter Meeting 2015. View Video

  • dentistryIQ

    Vigilant Biosciences closes $5.5 million Series B round of funding

    Funding will be used to support international launch of OncAlert Oral Cancer Risk Assessment System Vigilant Biosciences Inc., a developer of solutions that aid in the early detection and intervention of cancer, announced last week the successful completion of a…more

  • FDlogo

    Vigilant Biosciences reels in $5.5M for oral cancer test

    Vigilant Biosciences roped in $5.5 million in a Series B round to support development of its diagnostic system for the early detection of oral cancer, giving the company a boost as it eyes European and stateside approval for its product….more


©2011-2015 Vigilant Biosciences, Inc. All Rights Reserved.

×